Scaling Factors for the Extrapolation of In Vivo Metabolic Drug Clearance From In Vitro Data: Reaching a Consensus on Values of Human Micro-somal Protein and Hepatocellularity Per Gram of Liver

Cited by (418)

Items 201–300 of 418

1. Inter-individual Variability of In Vivo CYP2D6 Activity in Different Genotypes
   Kōji Chiba, Motohiro Kato, Takashi Ito, Toshio Suwa, Yuichi Sugiyama · 2012 · Drug Metabolism and Pharmacokinetics
2. Metabolism of speciociliatine, an overlooked kratom alkaloid for its potential pharmacological effects
   Shyam H Kamble, Erin C. Berthold, S. R. R. Kanumuri, Tamara I. King, Michelle A. Kuntz, Francisco León, Marco Mottinelli, L. McMahon, Christopher R. McCurdy, Abhisheak Sharma · 2022 · AAPS Journal
3. In vitro human metabolism of permethrin isomers alone or as a mixture and the formation of the major metabolites in cryopreserved primary hepatocytes
   Marie‐Emilie Willemin, Ali Kadar, Georges de Sousa, Éric Leclerc, Roger Rahmani, Céline Brochot · 2015 · Toxicology in Vitro
4. In Vitro–In Vivo Extrapolation by Physiologically Based Kinetic Modeling: Experience With Three Case Studies and Lessons Learned
   E. Algharably, E. Di Consiglio, E. Testai, F. Pistollato, H. Mielke, U. Gundert-Remy · 2022 · Frontiers in Toxicology
5. The development of a population physiologically based pharmacokinetic model for mycophenolic mofetil and mycophenolic acid in humans using data from plasma, saliva, and kidney tissue
   Mo’tasem M. Alsmadi, Mahdi Qasem Alfarah, Jawaher Albderat, Ghazi Alsalaita, Reham Issa Almardini, Salim Hamadi, Ahmad Al‐Ghazawi, Omar Abu‐Duhair, Nasir Idkaidek · 2019 · Biopharmaceutics & Drug Disposition
6. Application of Hybrid Approach Based on Empirical and Physiological Concept for Predicting Pharmacokinetics in Humans—Usefulness of Exponent on Prospective Evaluation of Predictability
   Hiroyuki Sayama, Hiroshi Komura, Motohiro Kogayu · 2012 · Drug Metabolism and Disposition
7. Conquering the beyond Rule of Five Space with an Optimized High-Throughput Caco-2 Assay to Close Gaps in Absorption Prediction
   Patricia Muschong, K. Awwad, Edward Price, Mario Mezler, Manuel Weinheimer · 2024 · Pharmaceutics
8. Predicting Intestinal and Hepatic First-Pass Metabolism of Orally Administered Testosterone Undecanoate
   Atheer Zgair, Yousaf Dawood, Suhaib M Ibrahem, Hyun-moon Back, L. Kagan, P. Gershkovich, Jong-Bong Lee · 2020 · Applied Sciences
9. Beyond the Michaelis‐Menten: Accurate Prediction of In Vivo Hepatic Clearance for Drugs With Low KM
   Hyun‐moon Back, Hwi‐yeol Yun, Sang Kyum Kim, Jae Kyoung Kim · 2020 · Clinical and Translational Science
10. Potential for pharmacokinetic interactions between Schisandra sphenanthera and bosutinib, but not imatinib: in vitro metabolism study combined with a physiologically‐based pharmacokinetic modelling approach
    Jeffry Adiwidjaja, A. Boddy, A. McLachlan · 2020 · British Journal of Clinical Pharmacology
11. Use of human liver and EpiSkin™ S9 subcellular fractions as a screening assays to compare the in vitro hepatic and dermal metabolism of 47 cosmetics‐relevant chemicals
    J. Eilstein, S. Grégoire, Aurélie Fabre, E. Arbey, C. Géniès, H. Duplan, H. Rothe, C. Ellison, R. Cubberley, A. Schepky et al. · 2020 · Journal of Applied Toxicology
12. Dialing in on pharmacological features for a therapeutic antioxidant small molecule
    Kayla N. Green, Kristof Pota, Gyula Tircsó, Réka Anna Gogolák, Olivia Kinsinger, Collin Davda, Kimberly Blain, Samantha M. Brewer, Paulina Gonzalez, Hannah M. Johnston et al. · 2019 · Dalton Transactions
13. Prediction of the Transporter-Mediated Drug-Drug Interaction Potential of Dabrafenib and Its Major Circulating Metabolites
    H. Ellens, Marta Johnson, Sarah K. Lawrence, Cory Watson, Liang-Fu Chen, L. Richards-Peterson · 2017 · Drug Metabolism And Disposition
14. Ontogeny of Scaling Factors for Pediatric Physiology-Based Pharmacokinetic Modeling and Simulation: Microsomal Protein Per Gram of Liver
    J. Leeder, J. Dinh, A. Gaedigk, Vincent S. Staggs, Bhagwat Prasad, R. Pearce · 2021 · Drug Metabolism And Disposition
15. Physiologically based kinetic modelling based prediction of in vivo rat and human acetylcholinesterase (AChE) inhibition upon exposure to diazinon
    Shensheng Zhao, S. Wesseling, B. Spenkelink, I. Rietjens · 2021 · Archives of Toxicology
16. An in vitromodel to quantify interspecies differences in kinetics for intestinal microbial bioactivation and detoxification of zearalenone
    Diana M Mendez-Catala, A. Spenkelink, I. Rietjens, K. Beekmann · 2020 · Toxicology Reports
17. The Segregated Intestinal Flow Model (SFM) for Drug Absorption and Drug Metabolism: Implications on Intestinal and Liver Metabolism and Drug–Drug Interactions
    K. Sandy Pang, Hao Peng, Keumhan Noh · 2020 · Pharmaceutics
18. Prediction of Losartan-Active Carboxylic Acid Metabolite Exposure Following Losartan Administration Using Static and Physiologically Based Pharmacokinetic Models.
    H. Nguyen, Jian Lin, E. Kimoto, Ernesto Callegari, Susanna Tse, R. Obach · 2017 · Journal of Pharmacy and Science
19. Discovery of novel 7-azaindoles as PDK1 inhibitors.
    Margarita Wucherer-Plietker, E. Merkul, Thomas J. J. Müller, C. Esdar, Thorsten Knöchel, T. Heinrich, H. Buchstaller, H. Greiner, D. Dorsch, D. Finsinger et al. · 2016 · Bioorganic & Medicinal Chemistry Letters
20. An Integrated Biophysical Model for Predicting the Clinical Pharmacokinetics of Transdermally Delivered Compounds.
    Mahadevabharath R. Somayaji, Debarun Das, H. T. Garimella, Carrie L. German, A. Przekwas, L. Simon · 2021 · European Journal of Pharmaceutical Sciences
21. Hepatic Scaling Factors for In Vitro–In Vivo Extrapolation of Metabolic Drug Clearance in Patients with Colorectal Cancer with Liver Metastasis
    Areti-Maria Vasilogianni, B. Achour, D. Scotcher, S. Peters, Z. Al-Majdoub, J. Barber, A. Rostami-Hodjegan · 2021 · Drug Metabolism And Disposition
22. Enhancement of the Antioxidant Activity and Neurotherapeutic Features through Pyridol Addition to Tetraazamacrocyclic Molecules
    Hannah M. Johnston, Kristof Pota, Madalyn M. Barnett, Olivia Kinsinger, Paige N Braden-Kuhle, Timothy M. Schwartz, Emily Hoffer, Nishanth S. Sadagopan, Nam Nguyen, Yu Yu et al. · 2019 · Inorganic Chemistry
23. Systemic clearance and brain distribution of carbazole-based cyanine compounds as Alzheimer’s disease drug candidates
    Wei Zhou, Xiaohui Hu, Kin-Yip Tam · 2017 · Scientific Reports
24. Age-Dependent Activity of the Uptake Transporters Ntcp and Oatp1b2 in Male Rat Hepatocytes: From Birth Till Adulthood
    S. Fattah, P. Augustijns, P. Annaert · 2015 · Drug Metabolism And Disposition
25. Malabaricone C-containing mace extract inhibits safrole bioactivation and DNA adduct formation both in vitro and in vivo.
    E. Martati, Rungnapa Boonpawa, J. V. D. van den Berg, A. Paini, A. Spenkelink, A. Punt, J. Vervoort, P. van Bladeren, I. Rietjens · 2014 · Food and Chemical Toxicology
26. Pharmacokinetics and ADME Characterization of Intravenous and Oral [14C]-Linerixibat in Healthy Male Volunteers
    M. Zamek-Gliszczynski, David Kenworthy, David A. Bershas, M. Sanghvi, Adrian I. Pereira, Jennypher Mudunuru, Lee Crossman, Jill L. Pirhalla, Karl M. Thorpe, Jeremy M. T. J. Dennison et al. · 2021 · Drug Metabolism And Disposition
27. Predicting human pharmacokinetics from preclinical data: clearance
    D. Yim, S. Bae, Suein Choi · 2021 · Translational and Clinical Pharmacology
28. Assessing CYP2C19 Ontogeny in Neonates and Infants Using Physiologically Based Pharmacokinetic Models: Impact of Enzyme Maturation Versus Inhibition
    P. Duan, Fang Wu, Jason N Moore, J. Fisher, V. Crentsil, Daniel Gonzalez, Lei Zhang, G. Burckart, Jian Wang · 2018 · CPT: Pharmacometrics & Systems Pharmacology
29. Inhibition of cytochrome P450 enzymes by saturated and unsaturated fatty acids in human liver microsomes, characterization of enzyme kinetics in the presence of bovine serum albumin (0.1 and 1.0% w/v) and in vitro – in vivo extrapolation of hepatic clearance
    R. Palacharla, Venkatesham Uthukam, Arunkumar Manoharan, R. Ponnamaneni, N. Padala, R. Boggavarapu, G. Bhyrapuneni, D. Ajjala, R. Nirogi · 2017 · European Journal of Pharmaceutical Sciences
30. Linking in Vitro Lipolysis and Microsomal Metabolism for the Quantitative Prediction of Oral Bioavailability of BCS II Drugs Administered in Lipidic Formulations.
    Paloma Benito-Gallo, M. Marlow, Vanessa Zann, P. Scholes, P. Gershkovich · 2016 · Molecular Pharmaceutics
31. Verapamil hepatic clearance in four preclinical rat models: towards activity‐based scaling
    J. Nicolaï, T. de Bruyn, P. Van Veldhoven, J. Keemink, P. Augustijns, Pieter Annaert · 2015 · Biopharmaceutics & drug disposition
32. Target-mediated drug disposition and prolonged liver accumulation of a novel humanized anti-CD81 monoclonal antibody in cynomolgus monkeys
    V. Vexler, Li Yu, Chandrasena R Pamulapati, Rosario Garrido, H. Grimm, P. Sriraman, Sandhya Bohini, Michael Schraeml, U. Singh, Michael Brandt et al. · 2013 · mAbs
33. Reaction Phenotyping of Low-Turnover Compounds in Long-Term Hepatocyte Cultures Through Persistent Selective Inhibition of Cytochromes P450
    S. Smith, Mike Lyman, B. Ma, D. Tweedie, Karsten Menzel · 2021 · Drug Metabolism And Disposition
34. Development, Testing, Parameterization, and Calibration of a Human Physiologically Based Pharmacokinetic Model for the Plasticizer, Hexamoll® Diisononyl-Cyclohexane-1, 2-Dicarboxylate Using In Silico, In Vitro, and Human Biomonitoring Data
    K. McNally, C. Sams, G. Loizou · 2019 · Frontiers in Pharmacology
35. Importance of in vitro conditions for modeling the in vivo dose in humans by in vitro–in vivo extrapolation (IVIVE)
    E. Algharably, R. Kreutz, U. Gundert-Remy · 2019 · Archives of Toxicology
36. Inter-individual Variability in Activity of the Major Drug Metabolizing Enzymes in Liver Homogenates of 20 Individuals.
    Shalenie P. den Braver-Sewradj, M. D. den Braver, M. V. van Dijk, Yong-Jie Zhang, Stefan J. Dekker, Lukas Wijaya, Nico P. E. Vermeulen, L. Richert, J. Commandeur, J. C. Vos · 2018 · Current drug metabolism
37. Challenges and Opportunities for Increasing the Knowledge Base Related to Drug Biotransformation and Pharmacokinetics during Growth and Development
    J. Leeder, B. Meibohm · 2016 · Drug Metabolism And Disposition
38. Evaluation of the interindividual human variation in bioactivation of methyleugenol using physiologically based kinetic modeling and Monte Carlo simulations.
    A. A. Al-Subeihi, Wasma Alhusainy, R. Kiwamoto, B. Spenkelink, P. van Bladeren, I. Rietjens, A. Punt · 2015 · Toxicology and Applied Pharmacology
39. Microsomal protein per gram of liver (MPPGL) in paediatric biliary atresia patients
    L. De Bock, K. Boussery, R. de Bruyne, M. Van Winckel, X. Stephenne, E. Sokal, J. Van Bocxlaer · 2014 · Biopharmaceutics & drug disposition
40. Modelling the Fate of Chemicals in Humans Using a Lifetime Physiologically Based Pharmacokinetic (PBPK) Model in MERLIN-Expo
    C. Brochot, Paul Quindroit · 2018 · The handbook of environmental chemistry
41. Cytochrome P450 metabolism and inhibition: analysis for drug discovery.
    B. Jones, D. Middleton, K. Youdim · 2009 · Progress in Medicinal Chemistry
42. Challenges and Opportunities for In Vitro–In Vivo Extrapolation of Aldehyde Oxidase-Mediated Clearance: Toward a Roadmap for Quantitative Translation
    N. Izat, Jayaprakasam Bolleddula, Armina Abbasi, Lionel Cheruzel, Robert S. Jones, Darren Moss, Fátima Ortega-Muro, Yannick Parmentier, Vincent C. Peterkin, Dan-Dan Tian et al. · 2023 · Drug Metabolism And Disposition
43. Estimation of FMO3 Ontogeny by Mechanistic Population Pharmacokinetic Modelling of Risdiplam and Its Impact on Drug–Drug Interactions in Children
    Y. Cleary, H. Kletzl, P. Grimsey, K. Heinig, K. Ogungbenro, H. Silber-Baumann, N. Frey, L. Aarons, A. Galetin, Michael Gertz · 2023 · Clinical Pharmacokinetics
44. Beyond the Michaelis–Menten: Accurate Prediction of Drug Interactions Through Cytochrome P450 3A4 Induction
    Ngoc-Anh Thi Vu, Yun-Min Song, Q. Tran, Hwi-yeol Yun, S. K. Kim, J. Chae, Jae Kyoung Kim · 2022 · Clinical pharmacology and therapy
45. Population pharmacokinetic model to generate mechanistic insights in bile acid homeostasis and drug-induced cholestasis
    Véronique M P de Bruijn, Ivonne M.C.M. Rietjens, Hans Bouwmeester · 2022 · Archives of Toxicology
46. Development and Biological Characterization of a Novel Selective TrkA Agonist with Neuroprotective Properties against Amyloid Toxicity
    Thanasis Rogdakis, Despoina Charou, Alessia Latorrata, Eleni Papadimitriou, Alexandros Tsengenes, Christina Athanasiou, Maria Anna Papadopoulou, Constantina Chalikiopoulou, Θεοδώρα Κάτσιλα, Isbaal Ramos et al. · 2022 · Biomedicines
47. Quantification of the irreversible fibroblast growth factor receptor inhibitor futibatinib by UPLC-MS/MS: Application to the metabolic stability assay in human liver microsomes for the estimation of its in vitro hepatic intrinsic clearance.
    Lloyd Wei Tat Tang, Eric Chun Yong Chan · 2022 · Journal of Pharmaceutical and Biomedical Analysis
48. Incorporation of in vitro metabolism data and physiologically based pharmacokinetic modeling in a risk assessment for chloroprene
    H. Clewell, Jerry L. Campbell, C. Van Landingham, A. Franzen, M. Yoon, D. Dodd, M. Andersen, P. Gentry · 2019 · Inhalation Toxicology
49. Development and application of a human PBPK model for bromodichloromethane to investigate the impacts of multi‐route exposure
    Elaina M. Kenyon, Christopher R. Eklund, Teresa L. Leavens, Rex A. Pegram · 2015 · Journal of Applied Toxicology
50. Predicting lung dosimetry of inhaled particleborne benzo[a]pyrene using physiologically based pharmacokinetic modeling
    Jerry L. Campbell, A. Franzen, C. Van Landingham, Michael H. Lumpkin, S. Crowell, C. Meredith, A. Loccisano, R. Gentry, H. Clewell · 2016 · Inhalation Toxicology
51. The application of global sensitivity analysis in the development of a physiologically based pharmacokinetic model for m-xylene and ethanol co-exposure in humans
    George D. Loizou, Kevin McNally, Kate Jones, John Cocker · 2015 · Frontiers in Pharmacology
52. Assessing the impact of child/adult differences in hepatic first-pass effect on the human kinetic adjustment factor for ingested toxicants
    Mathieu Valcke, Kannan Krishnan · 2012 · Regulatory Toxicology and Pharmacology
53. Probe ADME and Test Hypotheses: a PATH beyond clearance in vitro–in vivo correlations in early drug discovery
    L. Bell, Jianling Wang · 2012 · Expert Opinion on Drug Metabolism & Toxicology
54. Development of Next-Generation Antimalarial Acridones with Radical Cure Potential
    Rozalia A. Dodean, Yue-Xin Li, Xiaowei Zhang, Diana Caridha, Michael S Madejczyk, Xian-Nu Jin, William E Dennis, Ravi Chetree, Karl Kudyba, Sharon McEnearney et al. · 2025 · Journal of Medicinal Chemistry
55. A guide to developing population files for physiologically‐based pharmacokinetic modeling in the Simcyp Simulator
    Liam Curry, Sarah Alrubia, Frédéric Y. Bois, Ruth Clayton, Eman El‐Khateeb, Trevor N. Johnson, Muhammad Faisal, Sibylle Neuhoff, Kris Wragg, Amin Rostami‐Hodjegan · 2024 · CPT Pharmacometrics & Systems Pharmacology
56. CYP2J2-mediated metabolism of arachidonic acid in heart: A review of its kinetics, inhibition and role in heart rhythm control.
    Jacqueline Wen Hui Leow, Eric Chun Yong Chan · 2024 · Pharmacology and Therapeutics
57. In vitro-in vivo correlation of the chiral pesticide prothioconazole after interaction with human CYP450 enzymes.
    I. S. Perovani, Maike Felipe Santos Barbetta, Rodrigo Moreira da Silva, N. Lopes, Anderson Rodrigo Moraes de Oliveira · 2022 · Food and Chemical Toxicology
58. LC-MS/MS method for the quantification of the anti-cancer agent infigratinib: Application for estimation of metabolic stability in human liver microsomes.
    G. A. Mostafa, A. Kadi, N. AlMasoud, M. Attwa, Nasser S. Al-Shakliah, H. Alrabiah · 2021 · Journal of chromatography. B, Analytical technologies in the biomedical and life sciences
59. Characterization of phase I and phase II metabolites of hop (Humulus lupulus L.) bitter acids: In vitro and in vivo metabolic profiling by UHPLC-Q-Orbitrap.
    E. Salviati, E. Sommella, Albino Carrizzo, V. Di Sarno, A. Bertamino, Eleonora Venturini, C. Vecchione, P. Campiglia · 2021 · Journal of Pharmaceutical and Biomedical Analysis
60. Parameterization of Microsomal and Cytosolic Scaling Factors: Methodological and Biological Considerations for Scalar Derivation and Validation
    Michael J Doerksen, Robert S. Jones, M. Coughtrie, A. Collier · 2020 · European journal of drug metabolism and pharmacokinetics
61. Development of a Physiologically Based Pharmacokinetic Model for Sinogliatin, a First-in-Class Glucokinase Activator, by Integrating Allometric Scaling, In Vitro to In Vivo Exploration and Steady-State Concentration–Mean Residence Time Methods: Mechanistic Understanding of its Pharmacokinetics
    Ling Song, Yi Zhang, Ji Jiang, Shuang Ren, Li Chen, Dong-Yang Liu, Xi-Jing Chen, P. Hu · 2018 · Clinical Pharmacokinetics
62. Stereoselective Glucuronidation of Ornidazole in Humans: Predominant Contribution of UDP-Glucuronosyltransferases 1A9 and 2B7
    Jiang-bo Du, Tiangeng You, Xiao-Yan Chen, D. Zhong · 2013 · Drug Metabolism And Disposition
63. Prediction of Human Pharmacokinetics
    S. C. Khojasteh, H. Wong, C. Hop · 2011 · Springer eBooks
64. Human Internal Exposures of Bisphenol A and Six Data-Poor Analogs Predicted by Physiologically Based Kinetic Models with Multimodal Parametrization
    H. Bigonne, Amrei Rolof, Inga Potapova, S. Sturla, Georg Aichinger · 2025 · Environmental Science and Technology
65. Absorption, distribution, metabolism, excretion (ADME), drug-drug interaction potential and prediction of human pharmacokinetics of SUVN-G3031, a novel histamine 3 receptor (H3R) inverse agonist in clinical development for the treatment of narcolepsy
    Ramakrishna V. S. Nirogi, Gopinadh Bhyrapuneni, Nageswara Rao Muddana, Arunkumar Manoharan, Anil Karbhari Shinde, Abdul Rasheed Mohammed, Nagasurya Prakash Padala, Devender Reddy Ajjala, Ramkumar Subramanian, Veera Raghava Chowdary Palacharla · 2020 · European Journal of Pharmaceutical Sciences
66. Antimicrobial Peptides from Rat-Tailed Maggots of the Drone Fly Eristalis tenax Show Potent Activity against Multidrug-Resistant Gram-Negative Bacteria
    R. Hirsch, J. Wiesner, A. Bauer, Alexander Marker, H. Vogel, P. Hammann, A. Vilcinskas · 2020 · Microorganisms
67. Food ingredient safety evaluation: Utility and relevance of toxicokinetic methods
    Shruti V. Kabadi, Yu Zang, Jeffrey W. Fisher, Nikki Smith, Catherine Whiteside, Jason L. Aungst · 2019 · Toxicology and Applied Pharmacology
68. Preservation, induction or incorporation of metabolism into the in vitro cellular system - views to current opportunities and limitations.
    O. Pelkonen, M. Turpeinen, J. Hakkola, Khaled Abass, M. Pasanen, H. Raunio, K. Vähäkangas · 2013 · Toxicology in Vitro
69. Evaluation of the novel in vitro systems for hepatic drug clearance and assessment of their predictive utility
    James Brian. Houston, K Rowland‐Yeo, Ugo Zanelli · 2012 · Toxicology in Vitro
70. Novel tacrine-based multi-target directed Ligands: Enhancing cholinesterase inhibition, NMDA receptor antagonism, and CNS bioavailability for Alzheimer's disease treatment.
    B. Svobodová, Zuzana Moravcova, A. Misiachna, Gabriela Nováková, Aleš Marek, Vladimir Finger, Jitka Odvarkova, Jaroslav Pejchal, J. Karasova, Jakub Netolicky et al. · 2025 · European journal of medicinal chemistry
71. AI Promoted Virtual Screening, Structure-Based Hit Optimization, and Synthesis of Novel COVID-19 S-RBD Domain Inhibitors
    I. Gkekas, S. Katsamakas, Stelios K. Mylonas, T. Fotopoulou, George E. Magoulas, Alia Cristina Tenchiu, Marios Dimitriou, A. Axenopoulos, Nafsika Rossopoulou, Simona Kostova et al. · 2024 · Journal of Chemical Information and Modeling
72. In vitro–in silico-based prediction of inter-individual and inter-ethnic variations in the dose-dependent cardiotoxicity of R- and S-methadone in humans
    Miao-Ying Shi, Yu-Meng Dong, H. Bouwmeester, I. Rietjens, M. Strikwold · 2022 · Archives of Toxicology
73. Inter-individual variation in chlorpyrifos toxicokinetics characterized by physiologically based kinetic (PBK) and Monte Carlo simulation comparing human liver microsome and Supersome™ cytochromes P450 (CYP)-specific kinetic data as model input
    Shensheng Zhao, Sebastiaan Wesseling, Ivonne M.C.M. Rietjens, Marije Strikwold · 2022 · Archives of Toxicology
74. A Novel Method for Assessing Drug Degradation Product Safety Using Physiologically-Based Pharmacokinetic Models and Stochastic Risk Assessment.
    H. Nguyen, S. Stamatis, L. Kirsch · 2015 · Journal of Pharmacy and Science
75. Reprint of PopGen: A virtual human population generator
    Kevin McNally, Richard Cotton, Alex Hogg, George D. Loizou · 2015 · Toxicology
76. Methods for Determination of Enzyme Kinetics and Metabolic Rates
    Murali Subramanian, Timothy S. Tracy · 2012 · Encyclopedia of Drug Metabolism and Interactions
77. Exploratory population pharmacokinetics (e-PPK) analysis for predicting human PK using exploratory ADME data during early drug discovery research
    K. Tabata, Nozomu Hamakawa, S. Sanoh, S. Terashita, T. Teramura · 2009 · European journal of drug metabolism and pharmacokinetics
78. Toxicokinetics: A Guidance for Assessing Systemic Exposure in Toxicology Studies, Where Are We Now; An S3A/S3B Update (1995–2011)
    B. Campbell, B. Ings · 2013 · AAPS advances in the pharmaceutical sciences series
79. Establishing a physiologically based pharmacokinetic framework for aldehyde oxidase and dual aldehyde oxidase‐CYP substrates
    N. Izat, Jayaprakasam Bolleddula, Pasquale Carione, Leticia Huertas-Valentín, Robert S. Jones, Priyanka Kulkarni, Darren Moss, Vincent C. Peterkin, Dan-Dan Tian, A. Treyer et al. · 2024 · CPT: Pharmacometrics & Systems Pharmacology
80. Contribution of UGT Enzymes to Human Drug Metabolism Stereoselectivity: A Case Study of Medetomidine, RO5263397, Propranolol, and Testosterone
    Nicoló Milani, Na-Hong Qiu, S. Fowler · 2022 · Drug Metabolism And Disposition
81. A new approach methodology (NAM) for the prediction of (nor)ibogaine-induced cardiotoxicity in humans.
    Miao-Ying Shi, S. Wesseling, H. Bouwmeester, I. Rietjens · 2021 · ALTEX
82. Are body surface area based estimates of liver volume applicable to children with overweight or obesity? An in vivo validation study
    Chelsea Hosey‐Cojocari, S. Chan, Chance S. Friesen, Amie L. Robinson, Veronica Williams, E. Swanson, D. O'Toole, J. Radford, N. Mardis, T. Johnson et al. · 2021 · Clinical and Translational Science
83. Transport-Metabolism Interplay of Atazanavir in Rat Hepatocytes
    J. Nicolaï, T. de Bruyn, Louise Thevelin, P. Augustijns, P. Annaert · 2016 · Drug Metabolism And Disposition
84. Intestinal in vitro transport assay combined with physiologically based kinetic modeling as a tool to predict bile acid levels in vivo.
    V. D. de Bruijn, Willem Te Kronnie, I. Rietjens, H. Bouwmeester · 2023 · ALTEX
85. Comparative pharmacokinetics of baicalin and geniposide in juvenile and adult rats after oral administration of Qingkailing Granules
    Ting-Ting Li, Zhong Li, Xiao-Yan Yang, Xin-Yu Zhao, Xu Zhang, Xin-Bo Zhao, Song-Po Wang, Xiao-Kui Huo, Xiaoen Shi · 2020 · Chinese Herbal Medicines
86. Proteomic characterisation of drug metabolising enzymes and drug transporters in pig liver
    Yasmine Elmorsi, Hajar Al Feteisi, Z. Al-Majdoub, J. Barber, A. Rostami-Hodjegan, B. Achour · 2020 · Xenobiotica; the fate of foreign compounds in biological systems
87. Co-administration of Fluvastatin and CYP3A4 and CYP2C8 Inhibitors May Increase the Exposure to Fluvastatin in Carriers of CYP2C9 Genetic Variants.
    Yuji Mukai, Masayuki Narita, Erika Akiyama, K. Ohashi, Yasutaka Horiuchi, Yuka Kato, T. Toda, A. Rane, N. Inotsume · 2017 · Biological and Pharmaceutical Bulletin
88. Computational pharmacokinetic modeling of organ-on-chip devices and microphysiological systems
    Andrzej J. Przekwas, Mahadevabharath R. Somayaji · 2019 · Elsevier eBooks
89. Development of a PBPK model of psilocybin/psilocin from Psilocybe cubensis (magic mushroom) in mice, rats, and humans
    Nilubon Thaoboonruang, Ornrat Lohitnavy, Kimheang Ya, Manupat Lohitnavy · 2025 · Scientific Reports
90. Prediction of Pharmacokinetics for CYP3A4-Metabolized Drugs in Pediatrics and Geriatrics Using Dynamic Age-Dependent Physiologically Based Pharmacokinetic Models
    Jing Dong J Han, Zexin Zhang, Xiaodong Liu, Hanyu Yang, Li Liu · 2025 · Pharmaceutics
91. Use of Physiologically Based Kinetic Modeling to Predict Deoxynivalenol Metabolism and Its Role in Intestinal Inflammation and Bile Acid Kinetics in Humans
    Jingxuan Wang, V. D. de Bruijn, I. Rietjens, Nynke I. Kramer, Hans Bouwmeester · 2023 · Journal of Agricultural and Food Chemistry
92. Physiologically based pharmacokinetic modeling: A promising tool for translational research and regulatory toxicology
    K. Fairman, Miao Li, Shruti V. Kabadi, A. Lumen · 2020 · Current Opinion in Toxicology
93. In vitro–in vivo extrapolation of metabolic clearance using human liver microsomes: factors showing variability and their normalization
    Keiichi Morita, Motohiro Kato, Toshiyuki Kudo, Kiyomi Ito · 2020 · Xenobiotica
94. Xenobiotic Metabolism in Alginate-Encapsulated Primary Human Hepatocytes Over Long Timeframes
    M. B. Phillips, Pergentino Balbuena-Venancio, J. Enders, Rachel L. Norini, Yoo-Sik Shim, E. Burgunder, Lavanya Rao, David Billings, Jenny M. Pedersen, J. Macdonald et al. · 2018 · Applied In Vitro Toxicology
95. A Semi-Physiologically Based Pharmacokinetic Model Describing the Altered Metabolism of Midazolam Due to Inflammation in Mice
    Ninad Varkhede, Nita J. Patel, William Chang, K. Ruterbories, M. L. Forrest · 2018 · Pharmaceutical Research
96. Prediction of Metabolic Clearance for Low-Turnover Compounds Using Plated Hepatocytes with Enzyme Activity Correction
    B. Ma, R. Eisenhandler, Yu-Hsin Kuo, P. Rearden, Y. Li, P. J. Manley, S. Smith, Karsten Menzel · 2016 · European journal of drug metabolism and pharmacokinetics
97. Calorie Restriction Increases P-Glycoprotein and Decreases Intestinal Absorption of Digoxin in Mice
    Helen J. Renaud, Curtis D. Klaassen, Iván L. Csanaky · 2016 · Drug Metabolism and Disposition
98. A Single-Species Approach Considering Additional Physiological Information for Prediction of Hepatic Clearance of Glycoprotein Derivate Therapeutics
    Patrick Poulin · 2011 · Clinical Pharmacokinetics
99. In Vitro Characterization of Sarizotan Metabolism: Hepatic Clearance, Identification and Characterization of Metabolites, Drug-Metabolizing Enzyme Identification, and Evaluation of Cytochrome P450 Inhibition
    D. Gallemann, Elmar Wimmer, Constance C. Höfer, A. Freisleben, M. Fluck, B. Ladstetter, H. Dolgos · 2010 · Drug Metabolism And Disposition
100. Translation of In Vitro Metabolic Data to Predict In Vivo Drug–Drug Interactions: IVIVE and Modeling and Simulations
     Amin Rostami‐Hodjegan · 2009 · Springer eBooks